Alphamab Oncology
9966.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.12B
Close$
Share Statistics
| Market cap | $7.12 Billion |
|---|---|
| Enterprise Value | $7.02 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.12 |
| Beta | 0.57 |
| Outstanding Shares | 966,732,000 |
Return
| Return on Equity | 3.53% |
|---|---|
| Return on Assets | 2.73% |
| Return on Invested Capital | -0.43% |
Valuation & Multiples
| P/E Ratio | -36.42 |
|---|---|
| PEG | 12.66 |
| Price to Sales | 7.05 |
| Price to Book Ratio | 7.05 |
| Enterprise Value to Revenue | 5.4 |
| Enterprise Value to EBIT | -933.6 |
| Enterprise Value to Net Income | 118 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.17 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
$-0.43
Average shareholder expectationRevenue Estimate
$4.45 M
Average shareholder expectationNext Earnings Call
Expected Date
March 30, 2027
EPS Estimate
$-0.62
Average shareholder expectationRevenue Estimate
$214.75 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Alphamab Oncology
515 employees
CEO: Ting Xu Alphamab Oncology operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, production, and market introduction of biological therapies for cancer. Its comprehensive product pipeline include...